Articles dans des revues avec comité de lecture (79)
20.
Johnson, K., Bertoli, M., Phillips, L., Töpf, A., Van Den Bergh, P., Vissing, J., Witting, N., Nafissi, S., Jamal-Omidi, S., Łusakowska, A., Kostera-Pruszczyk, A., Potulska-Chromik, A., Deconinck, N., Wallgren-Pettersson, C., Strang-Karlsson, S., Colomer, J., Claeys, K. G., De Ridder, W., Baets, J., von der Hagen, M., Fernández-Torrón, R., Zulaica Ijurco, M., Espinal Valencia, J. B., Hahn, A., Durmus, H., Willis, T., Xu, L., Valkanas, E., Mullen, T. T., Lek, M., MacArthur, D. D., & Straub, V. (2018). Detection of variants in dystroglycanopathy-associated genes through the application of targeted whole-exome sequencing analysis to a large cohort of patients with unexplained limb-girdle muscle weakness. Skeletal Muscle, 8(1), 23. doi:10.1186/s13395-018-0170-122.
Paternoster, L., Baijot, S., Deliens, G., Goemans, N., Servais, L., & Deconinck, N. (2018). Cognitive assessment in spinal muscular atrophy type 1-2 using eye tracking system. Neuromuscular disorders, 28(2), 55-56.23.
Baijot, S., Cevallos Barragan, C., Zarka, D., Leroy, A., Slama, H., Colin, C., Deconinck, N., Danna, B., & Chéron, G. (2017). EEG Dynamics of a Go/Nogo Task in Children with ADHD. Brain sciences, 7(12), 167-182. doi:10.3390/brainsci712016724.
Victor, R. G., Sweeney, L. H., Finkel, R. R., Deconinck, N., Byrne, B., Eagle, M., Goemans, N., Vandenborne, K., Dubrovsky, A. A., Topaloglu, H., Miceli, C. M., Furlong, P., Landry, J., Elashoff, R., Cox, D. A., & Tadalafil DMD Study Group, (2017). A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy. Neurology, 89(17), 1811-1820. doi:10.1212/WNL.000000000000457025.
Soblet, J., Dimov, I., Graf von Kalckreuth, C., Cano-Chervel, J., Baijot, S., Pelc, K., Sottiaux, M., Vilain, C., Smits, G., & Deconinck, N. (2017). BCL11A frameshift mutation associated with dyspraxia and hypotonia affecting the fine, gross, oral, and speech motor systems. American journal of medical genetics. Part A, 176(1), 201-208. doi:10.1002/ajmg.a.3847926.
Reggiani, C., Coppens, S., Sekhara, T., Dimov, I., Pichon, B., Lufin, N., Addor, M. C., Belligni, E. F., Digilio, M. C., Faletra, F., Ferrero, G. B., Gerard, M., Isidor, B., Joss, S., Niel-Bütschi, F., Perrone, M. D., Petit, F., Renieri, A., Romana, S., Topa, A., Vermeesch, J. R., Lenaerts, T., Casimir, G., Abramowicz, M., Bontempi, G., Vilain, C., Deconinck, N., & Smits, G. (2017). Novel promoters and coding first exons in DLG2 linked to developmental disorders and intellectual disability. Genome medicine, 9(1), 67. doi:10.1186/s13073-017-0452-y27.
Bertini, E., Dessaud, E., Mercuri, E., Muntoni, F., Kirschner, J., Reid, C., Lusakowska, A., Deconinck, N., Cuisset, J. M., Abitbol, J.-L., Scherrer, B., Ducray, P. S., Buchbjerg, J., Vianna, E., van der Pol, L. W., Vuillerot, C., Blaettler, T., Fontoura, P., & Olesoxime SMA Phase 2 Study Investigators, (2017). Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet neurology, 16(7), 513-522. doi:10.1016/S1474-4422(17)30085-629.
Palmigiano, A., Jaeken, J., Sturiale, L., Bua, R. O., Barone, R., Rymen, D., Régal, L., Deconinck, N., Dionisi-Vici, C., Fung, C.-W., & Garozzo, D. (2017). MALDI-MS profiling of serum O-glycosylation and N-glycosylation in COG5-CDG. Journal of mass spectrometry, 52(6), 372-377. doi:10.1002/jms.393631.
Verhelst, H., De Waele, L., Deconinck, N., Ceulemans, B., Willekens, B., & Van Coster, R. (2017). Multiple sclerosis in Belgian children: A multicentre retrospective study. European journal of paediatric neurology, 21(2), 358-366. doi:10.1016/j.ejpn.2016.10.005